

THERAVANCE INC  
Form 8-K  
September 22, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **September 22, 2010**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer Identification Number)

**901 Gateway Boulevard  
South San Francisco, California 94080  
(650) 808-6000**

## Edgar Filing: THERAVANCE INC - Form 8-K

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

Today at the European Respiratory Society Annual Congress in Barcelona, Spain, GlaxoSmithKline plc presented two oral presentations: Phase 2 study of RELOVAIR , a once-daily combination medicine of fluticasone furoate (FF), the inhaled corticosteroid (ICS), and vilanterol trifenate (VI), the long-acting beta2 agonist (LABA) in patients with chronic obstructive pulmonary disease (COPD) and Phase 2b study of VI in patients with asthma. RELOVAIR is being developed for the treatment of patients with COPD or asthma under the LABA collaboration between GSK and Theravance, Inc. The two presentations are filed as Exhibit 99.1 and Exhibit 99.2 to this report and are incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Safety and efficacy of fluticasone furoate/vilanterol trifenate (FF/VI) in COPD patients
Exhibit 99.2	24h duration of the novel long-acting $\beta$ 2 agonist vilanterol trifenate in uncontrolled asthma

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: September 22, 2010

By:

**/s/ Michael W. Aguiar**

**Michael W. Aguiar  
Chief Financial Officer**

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Safety and efficacy of fluticasone furoate/vilanterol trifenate (FF/VI) in COPD patients
Exhibit 99.2	24h duration of the novel long-acting $\beta$ 2 agonist vilanterol trifenate in uncontrolled asthma